Does aspirin prophylaxis reduce cardiovascular death or cancer mortality in people without prior CVD?
Routine use of aspirin for primary prevention is not warranted because the reduction in nonfatal MI is offset by bleeding risks without a mortality benefit.
Despite important reductions in nonfatal MI, aspirin prophylaxis in people without prior CVD does not lead to reductions in either cardiovascular death or cancer mortality. Because the benefits are further offset by clinically important bleeding events, routine use of aspirin for primary prevention is not warranted and treatment decisions need to be considered on a case-by-case basis.
Sreenivasa Rao Kondapally Seshasai (Tue,) studied this question.